On April 29, 2026, the U.S. Food and Drug Administration published a Request for Information (RFI) in the Federal Register titled "AI-Enabled Optimization of Early-Phase Clinical Trials Pilot Program" (91 FR 23100, Docket No. FDA-2026-N-4390). The notice sought public input on a proposed pilot exploring whether AI-enabled tools and data science methods can improve the efficiency, speed, and quality of decision-making in early-phase (Phase 1/2) clinical trials, while preserving FDA’s existing scientific and regulatory standards.
What the pilot program is meant to explore
Per the notice, FDA framed the pilot around several potential use cases for AI in early-phase trial conduct, including:
- Improving overall trial efficiency and reducing timelines
- Enhancing real-time safety monitoring
- Supporting dose-selection decisions
- Enabling more informed early go/no-go decisions on a candidate product
FDA framed these goals against a backdrop of maintaining its existing scientific and regulatory rigor and promoting what the notice describes as trustworthy AI systems — i.e., this was explicitly positioned as an exploratory pilot design exercise, not a proposed rule or new guidance document.
What FDA asked commenters to address
The RFI requested input across a defined set of topics rather than open-ended comment: scope and focus of the pilot, participant selection criteria, collaboration models (e.g., how sponsors, technology vendors, and FDA reviewers would interact), operational structure, timeline and milestones, and how lessons from the pilot would be shared publicly.
Timeline
- April 29, 2026 — RFI published in the Federal Register (91 FR 23100-23102), opening an initial 30-day comment period.
- May 28, 2026 — FDA published a comment-period extension notice.
- June 29, 2026 — Extended comment deadline.
As of this writing, the comment window has closed. FDA has not published a public synthesis of the comments received or announced pilot participants, a start date, or next steps in the Federal Register; organizations that submitted comments or are tracking the docket should continue to monitor federalregister.gov and regulations.gov docket FDA-2026-N-4390 directly for any follow-up notice, since FDA has not committed to a fixed timeline for announcing outcomes.
Why this matters for research administrators
Even though this specific RFI’s comment window is now closed, it is a useful signal of direction for institutions and sponsors running or supporting early-phase trials: FDA is actively soliciting operational input — not just algorithmic-validation input — on how AI tools might be woven into trial conduct, safety monitoring, and dosing decisions. Research administration offices, clinical trial offices, and sponsors that are already piloting AI-assisted monitoring, adaptive dosing support, or decentralized data capture in early-phase protocols should treat this RFI, and any follow-up FDA notice on it, as part of the same trajectory as FDA’s broader AI regulatory framework for drug development and medical devices.
Related CASRAI resources
- FDA AI Guidance: The Regulatory Framework for Artificial Intelligence in Drug Development and Medical Devices — for the broader regulatory context this pilot RFI sits within.
- Decentralized Clinical Trials (DCTs) — a related trend in technology-enabled early-phase trial conduct.
- Clinical Trial Protocol
- Clinical Research Administration — the CASRAI clinical-research hub.
Frequently asked questions
Is this RFI a proposed rule or new FDA guidance?
No. An RFI is a mechanism for FDA to gather public input before deciding whether and how to design a pilot program; it does not itself create binding requirements or new guidance.
Can I still submit a comment on docket FDA-2026-N-4390?
The formal comment period FDA announced closed June 29, 2026. Federal Register/regulations.gov dockets sometimes accept late comments for the administrative record even after the stated deadline, but they are not guaranteed to be considered in FDA’s decision-making the way timely comments are — check the docket directly for its current status before assuming a late submission will be reviewed.
Does this RFI apply to a specific therapeutic area?
The notice was not limited to a single therapeutic area; it addressed early-phase (Phase 1/2) clinical trial conduct generally.
